INULA GROUP acquired by ARDIAN

The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring

Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity

Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth

The acquisition of Acteon by Dentressangle represents a major turning point in the medtech’s trajectory, moving toward an aggressive buy-and-build strategy. The strategic rationale for this transaction centers on an "industrial-consolidation" play, merging the group’s industry-leading technical operational depth in ultrasonic surgery with the sponsor’s extensive expertise in executing international build-up operations

The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets

Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni)

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.

Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board